Zhenwei Su

696 total citations
12 papers, 589 citations indexed

About

Zhenwei Su is a scholar working on Biomedical Engineering, Biomaterials and Oncology. According to data from OpenAlex, Zhenwei Su has authored 12 papers receiving a total of 589 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Biomedical Engineering, 7 papers in Biomaterials and 5 papers in Oncology. Recurrent topics in Zhenwei Su's work include Nanoplatforms for cancer theranostics (8 papers), Nanoparticle-Based Drug Delivery (7 papers) and Immunotherapy and Immune Responses (3 papers). Zhenwei Su is often cited by papers focused on Nanoplatforms for cancer theranostics (8 papers), Nanoparticle-Based Drug Delivery (7 papers) and Immunotherapy and Immune Responses (3 papers). Zhenwei Su collaborates with scholars based in China, Denmark and New Zealand. Zhenwei Su's co-authors include Xintao Shuai, Zecong Xiao, Jinsheng Huang, Shisong Han, Yong Wang, Liteng Lin, Xingyu Jiang, Yongcheng An, Shaowei Dong and Chang Zou and has published in prestigious journals such as Advanced Materials, Biomaterials and Chemical Communications.

In The Last Decade

Zhenwei Su

12 papers receiving 587 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhenwei Su China 11 321 214 185 161 142 12 589
Bilan Wang China 13 248 0.8× 265 1.2× 187 1.0× 141 0.9× 148 1.0× 18 659
Xiqin Yang China 15 335 1.0× 283 1.3× 238 1.3× 142 0.9× 81 0.6× 16 644
Xuechao Jin China 8 224 0.7× 133 0.6× 167 0.9× 131 0.8× 91 0.6× 8 464
Candido G. Da Silva Netherlands 10 266 0.8× 213 1.0× 190 1.0× 209 1.3× 106 0.7× 16 541
Zhenzhong Zhang China 13 344 1.1× 191 0.9× 134 0.7× 181 1.1× 71 0.5× 21 586
Ngoc Ha Hoang South Korea 14 224 0.7× 214 1.0× 261 1.4× 84 0.5× 99 0.7× 19 592
Yongdan Zhao China 13 476 1.5× 286 1.3× 294 1.6× 290 1.8× 134 0.9× 20 782
Minglu Zhou China 14 257 0.8× 276 1.3× 165 0.9× 84 0.5× 91 0.6× 29 603
Lihuan Shang China 9 420 1.3× 186 0.9× 220 1.2× 218 1.4× 113 0.8× 11 598
Manisit Das United States 13 342 1.1× 279 1.3× 215 1.2× 338 2.1× 302 2.1× 17 810

Countries citing papers authored by Zhenwei Su

Since Specialization
Citations

This map shows the geographic impact of Zhenwei Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenwei Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenwei Su more than expected).

Fields of papers citing papers by Zhenwei Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenwei Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenwei Su. The network helps show where Zhenwei Su may publish in the future.

Co-authorship network of co-authors of Zhenwei Su

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenwei Su. A scholar is included among the top collaborators of Zhenwei Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenwei Su. Zhenwei Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Su, Zhenwei, Hamza Boucetta, Jinling Huang, et al.. (2024). Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs. Acta Pharmaceutica Sinica B. 14(11). 4665–4682. 12 indexed citations
3.
Su, Zhenwei, Shaowei Dong, Yao Chen, et al.. (2023). Microfluidics‐Enabled Nanovesicle Delivers CD47/PD‐L1 Antibodies to Enhance Antitumor Immunity and Reduce Immunotoxicity in Lung Adenocarcinoma. Advanced Science. 10(20). e2206213–e2206213. 26 indexed citations
4.
Xiao, Feng, et al.. (2023). Microfluidics‐enabled Serial Assembly of Lipid‐siRNA‐sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy. Advanced Materials. 35(13). e2209672–e2209672. 31 indexed citations
5.
Su, Zhenwei, Zecong Xiao, Jinsheng Huang, et al.. (2021). Dual-Sensitive PEG-Sheddable Nanodrug Hierarchically Incorporating PD-L1 Antibody and Zinc Phthalocyanine for Improved Immuno-Photodynamic Therapy. ACS Applied Materials & Interfaces. 13(11). 12845–12856. 47 indexed citations
6.
Su, Zhenwei, Shaowei Dong, Shan‐Chao Zhao, et al.. (2021). Novel nanomedicines to overcome cancer multidrug resistance. Drug Resistance Updates. 58(8). 100777–100777. 140 indexed citations
7.
Xiao, Zecong, Zhenwei Su, Shisong Han, et al.. (2020). Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy. Science Advances. 6(6). eaay7785–eaay7785. 130 indexed citations
8.
Su, Zhenwei, Zecong Xiao, Yong Wang, et al.. (2020). Codelivery of Anti‐PD‐1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Dual‐Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy. Small. 16(7). e1906832–e1906832. 102 indexed citations
9.
Peng, Yuan, Zhenwei Su, Xin Wang, et al.. (2020). Near-Infrared Light Laser-Triggered Release of Doxorubicin and Sorafenib from TemperatureSensitive Liposomes for Synergistic Therapy of Hepatocellular Carcinoma. Journal of Biomedical Nanotechnology. 16(9). 1381–1393. 11 indexed citations
10.
11.
Wang, Yiru, Tinghui Yin, Zhenwei Su, et al.. (2017). Highly uniform ultrasound-sensitive nanospheres produced by a pH-induced micelle-to-vesicle transition for tumor-targeted drug delivery. Nano Research. 11(7). 3710–3721. 27 indexed citations
12.
Wang, Yong, Hong Xiao, Jing Fang, et al.. (2015). Construction of negatively charged and environment-sensitive nanomedicine for tumor-targeted efficient siRNA delivery. Chemical Communications. 52(6). 1194–1197. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bilan Wang Breakdown of academic impact, for papers by Xiqin Yang Breakdown of academic impact, for papers by Xuechao Jin Breakdown of academic impact, for papers by Candido G. Da Silva Breakdown of academic impact, for papers by Zhenzhong Zhang Breakdown of academic impact, for papers by Ngoc Ha Hoang Breakdown of academic impact, for papers by Yongdan Zhao Breakdown of academic impact, for papers by Minglu Zhou Breakdown of academic impact, for papers by Lihuan Shang Breakdown of academic impact, for papers by Manisit Das
Rankless by CCL
2026